The study would deliver crucial data that could help PredictImmune validate PredictSURE IBD^TM in diverse patient populations.
 

PredictImmune has made its name by developing advanced tools for guiding treatment alternatives for diseases that are caused due to immune mediated diseases, like inflammatory bowel disease. Recently, the company made headlines when it announced the commencement of the PRECIOUS (Predicting Crohn’s and Colitis Outcomes in the United States) trial along with Crohn’s & Colitis Foundation.

For the record, the PRECIOUS trial is an observational, multi-center study of patients who suffer from active ulcerative colitis or Crohn’s disease and who are not treated with immunomodulators, biologics or systemic steroids.

Reports cite that the study would enroll a total of 200 patients from its 15 facilities present throughout the U.S. Moreover, patients enrolled by New York University/Bellevue will be the initial batch to enter the program. Also, after the collection of initial blood sample, the study would focus its resources on tracking patients’ progress for up to 12 months.

Patients from the study would be categorized at diagnosis into low-risk and high-risk cohorts using the company’s PredictSURE IBD^TM biomarker. Apparently, PredictSURE IBD^TM differentiates peoples based on the potential of suffering a serious disease course that would be categorized by the need for numerous escalations in therapy due to chronically active or frequently relapsing disease.

Speaking on the development, Paul Kinnon, CEO, PredictImmune, said that the company perceives this collaboration with Crohn’s & Colitis Foundation as a forward-looking step for both IBD and PredictImmune patients in the U.S.

Kinnon added that PredictImmune is thrilled to initiate the PRECIOUS trial, allowing them to extend its validation cohort and support the efficacy of the test in offering insights into the long-term course of the disease. Moreover, the study would propel both the firms one step closer to their vision of improving quality of life and disease outcomes for patients suffering from IBD.
 

Source Credit: https://www.predictimmune.com/predictimmune-and-the-crohns-colitis-foundation-announce-start-of-jointly-sponsored-study/